Update date
14 Nov 2023
NAVIDEA BIOPHARMACEUTICALS, INC. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q3 2023.
- Latest financial report
- 14 Nov 2023
- Company location
- Dublin, OH
- Fiscal year end
- 31 December
Company
Names, identifiers, and filing context for this profile.
1 identity field
SEC filing record 1 source field available
Shareable Research Card
NAVIDEA BIOPHARMACEUTICALS, INC. Financial Facts
NAVIDEA BIOPHARMACEUTICALS, INC. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q3 2023
- Latest reported value
- Current Ratio 0.56x
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2023
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2023.
- Most recent SEC facts end date on this page: 10 Nov 2023.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for NAVIDEA BIOPHARMACEUTICALS, INC.
Latest financial period: Q3 2023. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q3 2023
SEC-backed company facts were refreshed from filings filed on 14 Nov 2023.
Benchmark Context
How Current Ratio compares
Current Ratio is down about 6.7% versus the comparable prior period.
Compared with
Compared with NAVIDEA BIOPHARMACEUTICALS, INC.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Current Ratio already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2023.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Key facts
- NAVIDEA BIOPHARMACEUTICALS, INC. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q3 2023.
- Headline metric: Current Ratio 0.56x.
Change
- Current Ratio YoY change: -6.7%.
- Most recent SEC facts end date: 10 Nov 2023.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest SEC snapshot (2023-11-10) highlights Current Ratio 0.56x, Quick Ratio 0.51x, and Debt-to-equity -1.86x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
No market comparison
Low confidence
Fair value per share
$1.16
Market price
n/a
PEG ratio
n/a
Enterprise value
$119.26M
Equity value
$115.39M
DCF fair value scenarios
Bear
$0.8569
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Base
$1.16
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Bull
$1.64
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Market price market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Market price market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Market price market price / SEC EPS
Market cap is unavailable
P/S
n/a
Market price market cap / SEC revenue
Market cap is unavailable
P/B
n/a
Market price market cap / SEC equity
Market cap is unavailable
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $8.19M
- Trailing SEC FCF
- Reported FCF
- $8.19M
- Net income
- $15.18M
- EBITDA
- $10.13M
- Cash
- $3.86M
- Debt
- n/a
- Equity
- $3.27M
- Shares
- 99,364,154
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Ticker missing for issuer
- Debt missing: equity value treats debt as 0
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: market price is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare NAVIDEA BIOPHARMACEUTICALS, INC. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: -100%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
29.6/100
Weak Confidence low
Financial Health
- Current Ratio
- 0.56x
- Quick Ratio
- 0.51x
- Debt to Equity
- -1.86x
Strengths
No strong signals yet.
Watchpoints
Debt-to-equity and Revenues YoY
Key metrics snapshot
Current Ratio
0.56x
YoY: -6.7%
Quick Ratio
0.51x
YoY: -13%
Debt-to-equity
-1.86x
YoY: -24%
Revenues YoY
-100%
YoY:
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 0.56x | -6.7% |
| Quick Ratio | 0.51x | -13% |
| Debt-to-equity | -1.86x | -24% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | -100% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 100,084,385 | +209% |
| Common Stock, Shares, Outstanding | 100,084,385 | +211% |
| Weighted Average Number of Shares Outstanding, Basic | 99,364,154 | +223% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
CIK / security context first